Joel Schilling
Corporate Officer/Principal presso Sequoia Sciences, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Gary R. Eldridge | M | - |
Sequoia Sciences, Inc.
 Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 anni |
| William C. Rusnack | M | 79 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Joseph P. Conran | M | 78 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Mark O'Neil-Johnson | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Stephen M. Notestine | M | 74 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 anni |
| Michael J. Mertz | M | 53 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| James P. Bick | M | 63 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Michael Caparon | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 8 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Joel Schilling
- Contatti personali
